Carisma Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Carisma Therapeutics

10/08/2023 20:07

* Carisma Therapeutics Inc  CARM.OQ  reported a quarterly
adjusted
loss of 49 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 60 cents per share.
    * Revenue was $3.56 million​; analysts expected $1.07
million. 
    * Carisma Therapeutics Inc's reported EPS for the quarter
was a
loss of 49 cents​.
    * The mean earnings estimate of analysts had fallen by
about 24.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Carisma Therapeutics Inc shares had fallen by 36.3% this
quarter and gained 7.9% so far this year.
    * The company reported a quarterly loss of $19.88 million.
    * Wall Street's median 12-month price target for Carisma
Therapeutics Inc is $10.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 07:06 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.60          -0.49          Beat
 Mar. 31 2023      -0.89          -1.93          Missed
 Dec. 31 2022      -2.20          -0.80          Beat
 Sep. 30 2022      -1.60          2.00           Beat